Centre for Eye Research Australia (CERA) is aiming to understand what people know about gene therapy through a survey led by Associate Professor Guei-Sheung Liu, principal investigator and head of the Genetic Engineering Research Unit.
Liu and his team are interested in understanding the factors that influence people to undertake current and future gene therapies in order to inform the scientific community on how communication about future treatments should be delivered.
“It’s a little unusual for laboratory scientists to do this sort of research – we typically do work that is focused on understanding the biology of human cells,” Liu said.
“But now that we are introducing new technologies in treatments, we need to know how well the public understands these technologies and how they feel about it, so that we can think about introducing and integrating them into our healthcare system.”
Gene technology is opening the door to novel therapies for conditions that have previously been thought of as untreatable.
Several gene therapies are already available to patients, but new, emerging technologies may transform how future treatments are developed.
Knowing how the public views and understands these technologies is crucial to its future development.
“There has been a lot of development around traditional gene therapy over the last 10 years, with the aid of gene technology, particularly in eyecare, but little is known about what the public thinks about using gene technology to prevent, treat, or even diagnose disease,” Liu said.
His current research focuses on using gene technology to develop treatments for a range of inherited retinal diseases, such as retinitis pigmentosa and Usher syndrome.
“Gene technology is a cutting-edge method which might change the way we manage these conditions in the near future,” Liu said.
“New therapies are being developed to repair the faulty genes, or replace them with working ones, to maintain cell function. We hope to have a clear understanding of what the public knows, and how they feel about it.”
New treatments also have the potential to treat other common eye conditions including diabetic retinopathy, age-related macular degeneration and glaucoma.
Previous surveys undertaken at CERA have explored how people living with inherited eye disease view genetic testing to incorporate their lived experience into future research.
This new survey, which is now open to Australian residents aged 18 years or over, looks to understand what people know about genetic research, what influences their knowledge and decisions, and their outlook for the future of gene technology-based healthcare.
“As these treatments go from the bench side to the bedside, we want to know what people understand so we can improve how we communicate our work,” Liu said.
To take part in the survey, click here.
More reading
New gene therapy offers hope for dry AMD
Building Australia’s gene therapy capability
Sydney surgeon details first Luxturna gene therapy allowing patient to see stars
